Prevention and treatment of alloantibody-mediated kidney transplant rejection

Transplant International

Volumn 24, Issue 12, 2011, Pages 1142-1155

  Bartel, Gregor ^a   Schwaiger, Elisabeth ^a   Böhmig, Georg A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

antibody mediated rejection; apheresis; crossmatch; kidney transplantation

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; BORTEZOMIB; ECULIZUMAB; HLA ANTIGEN; IMMUNOGLOBULIN; RITUXIMAB;

ALLOIMMUNITY; ANTIBODY MEDIATED REJECTION; DRUG MEGADOSE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOADSORPTION; IMMUNOMODULATION; KIDNEY GRAFT REJECTION; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SPLENECTOMY;

ANTILYMPHOCYTE SERUM; COMPLEMENT INACTIVATING AGENTS; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSORBENT TECHNIQUES; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; PROTEASOME ENDOPEPTIDASE COMPLEX; TISSUE DONORS;

EID: 81155162406     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01309.x     Document Type: Review

References (140)

1. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O,. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2: 662.
2. Patel R, Terasaki PI,. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
3. Terasaki PI,. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
4. Colvin RB,. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046.
5. Racusen LC, Halloran PF, Solez K,. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004; 4: 1562.
6. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
7. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779.
8. Böhmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091.
9. Scornik JC, Guerra G, Schold JD, Srinivas TR, Dragun D, Meier-Kriesche HU,. Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant 2007; 7: 1808.
10. Bartel G, Wahrmann M, Exner M, et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transplant 2008; 8: 41.
11. Opelz G,. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 1570.
12. Zhang Q, Cecka JM, Gjertson DW, et al. HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation 2011; 91: 1153.
13. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558.
14. Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90: 1473.
15. Halloran PF, Schlaut J, Solez K, Srinivasa NS,. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550.
16. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333.
17. Regele H, Böhmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371.
18. Smith RN, Kawai T, Boskovic S, et al. Chronic antibody mediated rejection of renal allografts: pathological, serological and immunologic features in nonhuman primates. Am J Transplant 2006; 6: 1790.
19. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7: 1743.
20. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841.
21. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576.
22. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009; 9: 1826.
23. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56.
24. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192.
25. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520.
26. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
27. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
28. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
29. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555. Epub 2009/05/23.
30. Everly MJ,. A summary of bortezomib use in transplantation across 29 centers. In:, Cecka JM, Terasaki PI, eds. Clin Transpl 2009. Los Angeles, California, 2009: p. 323.
31. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277.
32. Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011; 91: 1218.
33. Wahrmann M, Haidinger M, Körmöczi GF, et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89: 1385.
34. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681.
35. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256. Epub 2004/12/08.
36. Kirubakaran MG, Disney AP, Norman J, Pugsley DJ, Mathew TH,. A controlled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation 1981; 32: 164.
37. Soulillou JP, Guyot C, Guimbretiere J, et al. Plasma exchange in early kidney graft rejection associated with anti-donor antibodies. Nephron 1983; 35: 158.
38. Allen NH, Dyer P, Geoghegan T, Harris K, Lee HA, Slapak M,. Plasma exchange in acute renal allograft rejection. A controlled trial. Transplantation 1983; 35: 425.
39. Bonomini V, Vangelista A, Frasca GM, Di Felice A, Liviano D'Arcangelo G,. Effects of plasmapheresis in renal transplant rejection. A controlled study. Trans Am Soc Artif Intern Organs 1985; 31: 698.
40. Böhmig GA, Wahrmann M, Regele H, et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007; 7: 117.
41. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758.
42. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631.
43. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242. Epub 2008/07/19.
44. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
45. Jordan SC, Toyoda M, Vo AA,. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol 2011; 7: 341.
46. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70: 1531.
47. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887.
48. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S,. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
49. Higgins R, Hathaway M, Lowe D, et al. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 2007; 84: 876.
50. Magee CC, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S,. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience. Transplantation 2008; 86: 96.
51. Thielke JJ, West-Thielke PM, Herren HL, et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009; 87: 268.
52. Higgins RM, Bevan DJ, Carey BS, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996; 348: 1208.
53. Haas M, Böhmig GA, Leko-Mohr Z, et al. Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant 2002; 17: 1503.
54. Lorenz M, Regele H, Schillinger M, et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation 2005; 79: 696.
55. Bartel G, Wahrmann M, Regele H, et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant 2010; 10: 2033.
56. Beimler JH, Morath C, Schmidt J, et al. Successful deceased-donor kidney transplantation in crossmatch-positive patients with peritransplant plasma exchange and Rituximab. Transplantation 2009; 87: 668.
57. Colovai AI, Vasilescu ER, Foca-Rodi A, et al. Acute and hyperacute humoral rejection in kidney allograft recipients treated with anti-human thymocyte antibodies. Hum Immunol 2005; 66: 501.
58. Tinckam KJ, Wood IG, Ji F, Milford EL,. ATG induction is associated with an increase in anti-HLA antibodies after kidney transplantation. Hum Immunol 2004; 65: 1281.
59. Zachary AA, Montgomery RA, Leffell MS,. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66: 364.
60. Masson E, Devillard N, Chabod J, et al. Misleading de novo detection of serum anti-HLA-A3 antibodies in kidney recipients having received ATG before transplantation. Hum Immunol 2010; 71: 170.
61. Regele H, Exner M, Watschinger B, et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 16: 2058.
62. Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ,. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13: 242.
63. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79: 1507.
64. Shah A, Nadasdy T, Arend L, et al. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 2004; 77: 1399.
65. Bächler K, Amico P, Hönger G, et al. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010; 10: 1254.
66. Tait BD, Hudson F, Cantwell L, et al. Review article: Luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton) 2009; 14: 247.
67. Amico P, Honger G, Steiger J, Schaub S,. Utility of the virtual crossmatch in solid organ transplantation. Curr Opin Organ Transplant 2009; 14: 656.
68. Vaidya S, Partlow D, Susskind B, Noor M, Barnes T, Gugliuzza K,. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay. Transplantation 2006; 82: 1524.
69. Zachary AA, Sholander JT, Houp JA, Leffell MS,. Using real data for a virtual crossmatch. Hum Immunol 2009; 70: 574.
70. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J,. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 1111.
71. Kosmoliaptsis V, Bradley JA, Peacock S, Chaudhry AN, Taylor CJ,. Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies. Transplantation 2009; 87: 813.
72. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S,. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681.
73. Vlad G, Ho EK, Vasilescu ER, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009; 70: 589.
74. Wahrmann M, Bartel G, Exner M, et al. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int 2009; 22: 982.
75. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
76. Hönger G, Wahrmann M, Amico P, Hopfer H, Böhmig GA, Schaub S,. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 2010; 89: 1471.
77. Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86: 820.
78. Gloor J, Stegall MD,. Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol 2010; 6: 297.
79. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010; 89: 1403.
80. Amico P, Hirt-Minkowski P, Hönger G, et al. Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations. Transpl Int 2011; 24: 560.
81. Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004; 78: 221.
82. Bingaman AW, Wright FH, Murphey CL,. Kidney paired donation in live-donor kidney transplantation. N Engl J Med 2010; 363: 1091.
83. Ferrari P, Fidler S, Wright J, et al. Virtual crossmatch approach to maximize matching in paired kidney donation. Am J Transplant 2011; 11: 272.
84. Montgomery RA,. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. Am J Transplant 2010; 10: 449.
85. Claas FH, Rahmel A, Doxiadis II,. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009; 88: 447.
86. Morath C, Beimler J, Opelz G, et al. An integrative approach for the transplantation of high-risk sensitized patients. Transplantation 2010; 90: 645.
87. Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II,. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 2004; 78: 190.
88. Duquesnoy RJ,. Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications. Tissue Antigens 2011; 77: 525.
89. Claas FH, Doxiadis II,. Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both. Curr Opin Organ Transplant 2009; 14: 410.
90. Brown CM, Abraham KA, O'Kelly P, Conlon PJ, Walshe JJ,. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transplant Proc 2009; 41: 3690.
91. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099.
92. Madan AK, Slakey DP, Becker A, et al. Treatment of antibody-mediated accelerated rejection using plasmapheresis. J Clin Apher 2000; 15: 180.
93. Lennertz A, Fertmann J, Thomae R, et al. Plasmapheresis in C4d-positive acute humoral rejection following kidney transplantation: a review of 4 cases. Ther Apher Dial 2003; 7: 529.
94. Abraham KA, Brown C, Conlon PJ, et al. Plasmapheresis as rescue therapy in accelerated acute humoral rejection. J Clin Apher 2003; 18: 103.
95. Slatinska J, Honsova E, Burgelova M, Slavcev A, Viklicky O,. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience. Ther Apher Dial 2009; 13: 108.
96. Pascual M, Saidman S, Tolkoff-Rubin N, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66: 1460.
97. Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652.
98. Gannedahl G, Ohlman S, Persson U, et al. Rejection associated with early appearance of donor-reactive antibodies after kidney transplantation treated with plasmapheresis and administration of 15-deoxyspergualin. A report of two cases. Transpl Int 1992; 5: 189.
99. Nojima M, Yoshimoto T, Nakao A, et al. Combined therapy of deoxyspergualin and plasmapheresis: a useful treatment for antibody-mediated acute rejection after kidney transplantation. Transplant Proc 2005; 37: 930.
100. Rocha PN, Butterly DW, Greenberg A, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75: 1490.
101. Becker YT, Becker BN, Pirsch JD, Sollinger HW,. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996.
102. Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277.
103. Koller H, Steurer W, Mark W, et al. Clearance of C4d deposition after successful treatment of acute humoral rejection in follow-up biopsies: a report of three cases. Transpl Int 2004; 17: 177.
104. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231.
105. Lonze BE, Dagher NN, Simpkins CE, et al. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant 2010; 10: 2154.
106. Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7: 842.
107. Kaplan B, Gangemi A, Thielke J, Oberholzer J, Sankary H, Benedetti E,. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007; 83: 99.
108. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800.
109. Casadei DH, del CRM, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71: 53.
110. Kaposztas Z, Podder H, Mauiyyedi S, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23: 63.
111. Persson NH, Bucin D, Ekberg H, et al. Immunoadsorption in acute vascular rejection after renal transplantation. Transplant Proc 1995; 27: 3466. (Pubitemid 26018586)
112. Pretagostini R, Berloco P, Poli L, et al. Immunoadsorption with protein A in humoral rejection of kidney transplants. ASAIO J 1996; 42: M645.
113. Hickstein H, Korten G, Bast R, et al. Protein A immunoadsorption (i.a.) in renal transplantation patients with vascular rejection. Transfus Sci 1998; 19 (Suppl.): 53.
114. Böhmig GA, Regele H, Säemann MD, et al. Role of humoral immune reactions as target for antirejection therapy in recipients of a spousal-donor kidney graft. Am J Kidney Dis 2000; 35: 667.
115. Böhmig GA, Regele H, Exner M, et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 2001; 12: 2482.
116. Habicht A, Regele H, Exner M, et al. A case of severe C4d-positive kidney allograft dysfunction in the absence of histomorphologic features of rejection. Wien Klin Wochenschr 2002; 114: 945.
117. Min L, Shuming J, Zheng T, et al. Novel rescue therapy for C4d-positive acute humoral renal allograft rejection. Clin Transplant 2005; 19: 51.
118. Theruvath TP, Saidman SL, Mauiyyedi S, et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001; 72: 77.
119. Schwarz C, Regele H, Huttary N, et al. Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy. Wien Klin Wochenschr 2006; 118: 397.
120. Akalin E, Sehgal V, Murphy B, et al. Intravenous immunoglobulin treatment in a kidney transplant patient with chronic allograft nephropathy. Transplantation 2005; 79: 257.
121. Billing H, Rieger S, Ovens J, et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008; 86: 1214.
122. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A,. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87: 1837.
123. Terasaki PI, Ozawa M,. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005; 80: 1194.
124. Bartel G, Regele H, Wahrmann M, et al. Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 2008; 8: 2652.
125. Böhmig GA, Bartel G, Regele H, Wahrmann M,. Prospects and limitations of post-transplantation alloantibody detection in renal transplantation. Hum Immunol 2009; 70: 640.
126. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487. Epub 2005/06/17.
127. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC,. Multiple myeloma. Lancet 2009; 374: 324. Epub 2009/06/23.
128. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Jr, Lee KP, Boise LH,. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907.
129. Groettrup M, Schmidtke G,. Selective proteasome inhibitors: modulators of antigen presentation? Drug Discov Today 1999; 4: 63.
130. Luo H, Wu Y, Qi S, Wan X, Chen H, Wu J,. A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 2001; 72: 196.
131. Blanco B, Perez-Simon JA, Sanchez-Abarca LI, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006; 107: 3575. Epub 2005/11/12.
132. Kim JS, Lee JI, Shin JY, et al. Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates. Transplantation 2009; 88: 1349.
133. Nencioni A, Schwarzenberg K, Brauer KM, et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 2006; 108: 551.
134. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748. Epub 2008/06/11.
135. Cascio P, Oliva L, Cerruti F, et al. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur J Immunol 2008; 38: 658. Epub 2008/02/07.
136. Stegall MD, Dean PG, Gloor J,. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant 2009; 9: 998.
137. Vogelbacher R, Meister S, Guckel E, et al. Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. Nephrol Dial Transplant 2010; 25: 3764.
138. Zimmerhackl LB, Hofer J, Cortina G, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010; 362: 1746.
139. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M,. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010; 89: 903.
140. Tillou X, Poirier N, Le Bas-Bernardet S, et al. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 2010; 78: 152.